Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein.

ABSTRACT: We herein report the design and synthesis of the first nanomolar binding inhibitor of STAT5 protein. Lead compound 13a, possessing a phosphotyrosyl-mimicking salicylic acid group, potently and selectively binds to STAT5 over STAT3, inhibits STAT5-SH2 domain complexation events in vitro, silences activated STAT5 in leukemic cells, as well as STAT5's downstream transcriptional targets, including MYC and MCL1, and, as a result, leads to apoptosis. We believe 13a represents a useful probe for interrogating STAT5 function in cells as well as being a potential candidate for advanced preclinical trials.

SUBMITTER: Cumaraswamy AA 

PROVIDER: S-EPMC4234445 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature